Last reviewed · How we verify
Spironolactone (drug)
Spironolactone blocks aldosterone receptors in the kidney to increase sodium and water excretion while retaining potassium.
Spironolactone blocks aldosterone receptors in the kidney to increase sodium and water excretion while retaining potassium. Used for Heart failure with reduced ejection fraction, Hypertension, Primary hyperaldosteronism.
At a glance
| Generic name | Spironolactone (drug) |
|---|---|
| Also known as | Aldactone®, Spironolactone |
| Sponsor | University of Sao Paulo General Hospital |
| Drug class | Potassium-sparing diuretic; Aldosterone antagonist |
| Target | Mineralocorticoid receptor (MR) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Spironolactone is a potassium-sparing diuretic and aldosterone antagonist that binds to mineralocorticoid receptors in the collecting duct of the nephron. By blocking aldosterone's effects, it prevents sodium reabsorption and potassium excretion, leading to increased urine output and reduced blood volume and blood pressure. It is also used for its anti-fibrotic and anti-inflammatory properties in heart failure and other conditions.
Approved indications
- Heart failure with reduced ejection fraction
- Hypertension
- Primary hyperaldosteronism
- Edema associated with cirrhosis or nephrotic syndrome
- Resistant hypertension
Common side effects
- Hyperkalemia
- Gynecomastia
- Menstrual irregularities
- Headache
- Dizziness
- Gastrointestinal disturbances
Key clinical trials
- Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke (PHASE2)
- Spironolactone for Pulmonary Arterial Hypertension (PHASE2)
- Spironolactone Improved Children With Gene Mutations Related to NCOR (PHASE2, PHASE3)
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- HEART: Pilot Randomized Controlled Trial (PHASE1, PHASE2)
- Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study (PHASE2)
- Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone (PHASE3)
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spironolactone (drug) CI brief — competitive landscape report
- Spironolactone (drug) updates RSS · CI watch RSS
- University of Sao Paulo General Hospital portfolio CI